{"id":"W2884001607","doi":"10.1016/s1470-2045(18)30333-4","title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"","keywords":"Nova (rocket); Placebo; Double blind; Medicine; Quality of life (healthcare); Oncology; Gynecology; Ovarian cancer; Internal medicine; Cancer; Alternative medicine; Pathology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001930427,0.001731155,0.004359964,0.0004394441,0.0003817713,0.001226151,0.00102449,0.001810765,0.005102219],"category_scores_gemma":[0.002473484,0.000822754,0.003561925,0.0005058197,0.001488743,0.001126305,0.0005850906,0.003325534,0.0005780099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007705707,"about_ca_system_score_gemma":0.0006993269,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009113073,"about_ca_topic_score_gemma":0.001333825,"domain_scores_codex":[0.9989373,0.0006064875,0.00009453463,0.0001848015,0.00006634548,0.0001104726],"domain_scores_gemma":[0.9988124,0.0004334668,0.000381573,0.0000845285,0.00005056504,0.0002373587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9872343,0.001251944,0.0005093189,0.0009549389,0.001391392,0.00001648926,0.00002817172,0.0001532128,0.0006474242,0.00003352488,0.000227083,0.007552096],"study_design_scores_gemma":[0.96739,0.0290608,0.001915313,0.00004971501,0.0008718938,0.00002131457,0.00001711288,0.0002175702,0.0001228227,0.00009480818,0.0002259019,0.00001272718],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9747477,0.01875635,0.000620008,0.0008033442,0.0008624348,0.001628539,0.0009766769,0.0001136368,0.001491361],"genre_scores_gemma":[0.989529,0.004717796,0.0008900227,0.0007508912,0.0005097387,0.001552608,0.0007359177,0.00001722642,0.00129685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005102219,"threshold_uncertainty_score":0.01706862,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1468114558995152,"score_gpt":0.4253526568431366,"score_spread":0.2785412009436214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}